A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection
Status: | Active, not recruiting |
---|---|
Conditions: | Infectious Disease, Hepatitis, Hepatitis, Hepatitis |
Therapuetic Areas: | Immunology / Infectious Diseases |
Healthy: | No |
Age Range: | 18 - 100 |
Updated: | 7/28/2016 |
Start Date: | September 2014 |
End Date: | January 2017 |
A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (SURVEYOR-II)
The purpose of this study is to evaluate the safety and efficacy of ABT-493 and ABT-530 (or
ABT-493/ABT-530) coadministered with and without ribavirin in adults with chronic HCV
genotypes 2, 3, 4, 5 or 6 infection.
In part 4, the primary objectives also include to assess the efficacy (SVR12) of treatment
with ABT-493/ABT-530 combination regimen in GT2-infected DAA-naive subjects without
cirrhosis compared to historical SVR12 rate of treatment with sofosbuvir plus RBV in
GT2-infected DAA-naive subjects without cirrhosis.
ABT-493/ABT-530) coadministered with and without ribavirin in adults with chronic HCV
genotypes 2, 3, 4, 5 or 6 infection.
In part 4, the primary objectives also include to assess the efficacy (SVR12) of treatment
with ABT-493/ABT-530 combination regimen in GT2-infected DAA-naive subjects without
cirrhosis compared to historical SVR12 rate of treatment with sofosbuvir plus RBV in
GT2-infected DAA-naive subjects without cirrhosis.
Inclusion Criteria:
- Male or female between at least 18 years of age at time of Screening
- Screening laboratory result indicating HCV Genotype 2, 3, 4, 5, or 6 infection.
- Chronic HCV infection.
- Subject must be either HCV treatment-naïve or treatment-experienced.
- Subject must be documented as non-cirrhotic or as having compensated cirrhosis (GT3
only).
Exclusion Criteria:
- History of severe, life-threatening or other significant sensitivity to any drug.
- Female who is pregnant, planning to become pregnant during the study, or
breastfeeding; or male whose partner is pregnant or planning to become pregnant
during the study.
- Recent (within 6 months prior to study drug administration) history of drug or
alcohol abuse that could preclude adherence to the protocol in the opinion of the
investigator.
- Positive test result at Screening for hepatitis B surface antigen (HBsAg) or
anti-human immunodeficiency virus antibody (HIV Ab).
- HCV genotype performed during screening indicating co-infection with more than one
HCV genotype.
We found this trial at
59
sites
Allentown, Pennsylvania
Principal Investigator: Site Reference ID/Investigator# 132608, MD
Click here to add this to my saved trials

Adelaide,
Principal Investigator: Site Reference ID/Investigator# 130887, MD
Click here to add this to my saved trials

Arlington, Texas 76017
Principal Investigator: Site Reference ID/Investigator# 130740, MD
Click here to add this to my saved trials

Asheville, North Carolina
Principal Investigator: Site Reference ID/Investigator# 132611, MD
Click here to add this to my saved trials

Atlanta, Georgia
Principal Investigator: Site Reference ID/Investigator# 132609, MD
Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Aurora, Colorado 80045
Principal Investigator: Site Reference ID/Investigator# 130737, MD
Click here to add this to my saved trials

Bakersfield, California 93301
Principal Investigator: Site Reference ID/Investigator# 130738, MD
Click here to add this to my saved trials

Baltimore, Maryland
Principal Investigator: Site Reference ID/Investigator# 130750, MD
Click here to add this to my saved trials

Click here to add this to my saved trials

Bastrop, Louisiana 71220
Principal Investigator: Site Reference ID/Investigator# 132917, MD
Click here to add this to my saved trials

Binghamton, New York 13901
Principal Investigator: Site Reference ID/Investigator# 130734, MD
Click here to add this to my saved trials

Birmingham, Alabama
Principal Investigator: Site Reference ID/Investigator# 132641, MD
Click here to add this to my saved trials

Catonsville, Maryland 21228
Principal Investigator: Site Reference ID/Investigator# 132631, MD
Click here to add this to my saved trials

Chevy Chase, Maryland 20815
Principal Investigator: Site Reference ID/Investigator# 135352, MD
Click here to add this to my saved trials

Chicago, Illinois
Principal Investigator: Site Reference ID/Investigator# 132606, MD
Click here to add this to my saved trials

Coronado, California 92118
Principal Investigator: Site Reference ID/Investigator# 132612, MD
Click here to add this to my saved trials

Dothan, Alabama 36303
Principal Investigator: Site Reference ID/Investigator# 130743, MD
Click here to add this to my saved trials

Durham, North Carolina
Principal Investigator: Site Reference ID/Investigator# 132622, MD
Click here to add this to my saved trials

Falls Church, Virginia 22042
Principal Investigator: Site Reference ID/Investigator# 132603, MD
Click here to add this to my saved trials

Germantown, Tennessee 38138
Principal Investigator: Site Reference ID/Investigator# 132649, MD
Click here to add this to my saved trials

Houston, Texas
Principal Investigator: Site Reference ID/Investigator# 132648, MD
Click here to add this to my saved trials

Click here to add this to my saved trials

Indianapolis, Indiana 46202
Principal Investigator: Site Reference ID/Investigator# 130745, MD
Click here to add this to my saved trials

Kansas City, Missouri 64108
Principal Investigator: Site Reference ID/Investigator# 132607, MD
Click here to add this to my saved trials

La Jolla, California 92093
Principal Investigator: Site Reference ID/Investigator# 132629, MD
Click here to add this to my saved trials

Lebanon, New Hampshire
Principal Investigator: Site Reference ID/Investigator# 132604, MD
Click here to add this to my saved trials

Los Angeles, California
Principal Investigator: Site Reference ID/Investigator# 130742, MD
Click here to add this to my saved trials

Click here to add this to my saved trials

Miami, Florida 33136
Principal Investigator: Site Reference ID/Investigator# 132627, MD
Click here to add this to my saved trials

Nashville, Tennessee 37232
Principal Investigator: Site Reference ID/Investigator# 132613, MD
Click here to add this to my saved trials

New York, New York 10032
Principal Investigator: Site Reference ID/Investigator# 132628, MD
Click here to add this to my saved trials

Click here to add this to my saved trials

Newark, New Jersey
Principal Investigator: Site Reference ID/Investigator# 132638, MD
Click here to add this to my saved trials

Newport News, Virginia 23601
Principal Investigator: Site Reference ID/Investigator# 132634, MD
Click here to add this to my saved trials

Novi, Michigan 48377
Principal Investigator: Site Reference ID/Investigator# 132610, MD
Click here to add this to my saved trials

Orlando, Florida 32804
Principal Investigator: Site Reference ID/Investigator# 132614, MD
Click here to add this to my saved trials

Philadelphia, Pennsylvania
Principal Investigator: Site Reference ID/Investigator# 132625, MD
Click here to add this to my saved trials

Phoenix, Arizona
Principal Investigator: Site Reference ID/Investigator# 130755, MD
Click here to add this to my saved trials

Pittsburgh, Pennsylvania
Principal Investigator: Site Reference ID/Investigator# 132630, MD
Click here to add this to my saved trials

Portland, Oregon
Principal Investigator: Site Reference ID/Investigator# 130739, MD
Click here to add this to my saved trials

Providence, Rhode Island
Principal Investigator: Site Reference ID/Investigator# 132642, MD
Click here to add this to my saved trials

Click here to add this to my saved trials

Rochester, New York
Principal Investigator: Site Reference ID/Investigator# 132620, MD
Click here to add this to my saved trials

Sacramento, California 95825
Principal Investigator: Site Reference ID/Investigator# 132602, MD
Click here to add this to my saved trials

San Antonio, Texas 78224
Principal Investigator: Site Reference ID/Investigator# 131529, MD
Click here to add this to my saved trials

San Diego, California
Principal Investigator: Site Reference ID/Investigator# 132601, MD
Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

Click here to add this to my saved trials

San Francisco, California
Principal Investigator: Site Reference ID/Investigator# 132600, MD
Click here to add this to my saved trials

Click here to add this to my saved trials

Seattle, Washington 98105
Principal Investigator: Site Reference ID/Investigator# 132637, MD
Click here to add this to my saved trials

Shreveport, Louisiana 71103
Principal Investigator: Site Reference ID/Investigator# 130733, MD
Click here to add this to my saved trials

St. Louis, Missouri 63104
Principal Investigator: Site Reference ID/Investigator# 132599, MD
Click here to add this to my saved trials

St. Paul, Minnesota 55114
Principal Investigator: Site Reference ID/Investigator# 132639, MD
Click here to add this to my saved trials
